TAVR or SAVR: Beyond the STS Score · Boston Scientific Abbot Vascular 2. 5/24/2017 2 Patient...

Post on 19-Aug-2020

2 views 0 download

transcript

5/24/2017

1

Juan Crestanello, MDDivision of Cardiac Surgery

TAVR or SAVR: Beyond the STS Score

1

Lakshmi Prasad Dasi, PhDDepartment of Biomedical Engineering

The Ohio State UniversityWexner Medical Center

Disclosures

Dr. Dasi

▪ NIH/NHLBI

▪ NIH/NIBIB

▪ NIH/NCAI

▪ AHA

Dr. Crestanello Research Grants from: Medtronic Boston Scientific Abbot Vascular

2

5/24/2017

2

Patient Selection for SAVR vs TAVR

ExtremeInnoperable

Risk

High Risk

TAVR

Intermediate Risk

LowRisk

SAVR

Risk ProfileSTS PROM + Frailty + Other Comorbidities

Moving Beyond Risk

Age-Life Expectancy-Valve Durability

Concomitant cardiac disease

Mitral valve disease

Coronary artery disease

Valve and Aortic Root Anatomy

Bicuspid Aortic Valve

LVOT Calcification

Small root-low lying coronary ostia

5/24/2017

3

Moving Beyond Risk

Age-Life Expectancy-Valve Durability

Concomitant cardiac disease

Mitral valve disease

Coronary artery disease

Valve and Aortic Root Anatomy

Bicuspid Aortic Valve

LVOT Calcification

Small root-low lying coronary ostia

Age and Life Expectancy: Longer Survival

6

32

24

17

8

0

10

20

30

40

50 60 70 80

Sur

viva

l (Y

ears

)

Age

21

1511

6

0

10

20

30

40

50 60 70 80

Sur

viva

l (Y

ears

)

Age

Survival General Population

Survival after Surgical AVR

Social Security Life Tables Birkmeyer et al. Ann Thorac Surg 2000

5/24/2017

4

Surgical Valve Durability

7

Freedom from Structural Valve Deterioration: Surgical AVR

Bourguinion et al. Ann Thorac Surg 2015

10-15 years

Age and Life Expectancy: Longer Survival

8

32

24

17

8

0

10

20

30

40

50 60 70 80

Sur

viva

l (Y

ears

)

Age

21

1511

6

0

10

20

30

40

50 60 70 80

Sur

viva

l (Y

ears

)

Age

Survival General Population

Survival after Surgical AVR

Freedom From SVD: Surgical AVR

Social Security Life Tables Birkmeyer et al. Ann Thorac Surg 2000

5/24/2017

5

Age and Life Expectancy: Longer Survival

9

32

24

17

8

0

10

20

30

40

50 60 70 80

Sur

viva

l (Y

ears

)

Age

21

1511

6

0

10

20

30

40

50 60 70 80S

urvi

val (

Yea

rs)

Age

Survival General Population

Survival after Surgical AVR

32% 21% 12% 3%

REOPERATION

Freedom From SVD: Surgical AVR

Social Security Life Tables Birkmeyer et al. Ann Thorac Surg 2000

10

TAVR Durability

5/24/2017

6

TAVR Durability

11

Age and Life Expectancy: Longer Survival

12

32

24

17

8

0

10

20

30

40

50 60 70 80

Sur

viva

l (Y

ears

)

Age

21

1511

6

0

10

20

30

40

50 60 70 80

Sur

viva

l (Y

ears

)

Age

Survival General Population

Survival after Surgical AVR

Freedom From SVD: TAVR

HIGHER REOPERATION

RATE

5/24/2017

7

Moving Beyond Risk

Age-Life Expectancy-Valve Durability

Concomitant cardiac disease

Mitral valve disease

Coronary artery disease

Ascending aortic aneurysms

Other

Valve and Aortic Root Anatomy

LVOT Calcification

Small root-low lying coronary ostia

Bicuspid Aortic Valve

Moving Beyond Risk

Age-Life Expectancy-Valve Durability

Concomitant cardiac disease

Mitral valve disease

Coronary artery disease

Ascending aortic aneurysms

Other

Valve and Aortic Root Anatomy

Annular and LVOT Calcification

Small root-low lying coronary ostia

Bicuspid Aortic Valve

5/24/2017

8

15

Annular and LVOT Calcification

Valve UnderexpansionParavalvular LeakAnnular Rupture

LVOT Calcification

16

Annular and LVOT Calcification

Paravalvular Leak- opposing side

5/24/2017

9

17

Annular and LVOT Calcification

Aortic View Annular View

Finite element modeling

Crimping stores energy into the nitinol valve frame

Valve frame does work to push calcified leaflets open

18

Annular and LVOT Calcification

Stent conformation over calcification results in flow paths

Potential for predictive modeling to optimize

Placement

Device selection

5/24/2017

10

19

Annular and LVOT Calcification

Computational Fluid DynamicsSimulation

Potential to couple fluids simulations with finite element modeling for pre-operative planning

Moving Beyond Risk

Age-Life Expectancy-Valve Durability

Concomitant cardiac disease

Mitral valve disease

Coronary artery disease

Valve and Aortic Root Anatomy

Annular and LVOT Calcification

Small root-low lying coronary ostia

Bicuspid Aortic Valve

5/24/2017

11

Small Root – Low Lying Coronary Ostia

1-3% of population

More common in women

21

Small Root – Low Lying Coronary Ostia

22

The flow area for coronary bound flow can be complex due to:

Height, calcification, and width

Simulations and/or geometrically aligned indices better predict than just height

5/24/2017

12

Small Root – Low Lying Coronary Ostia

23

Device specific variation in leaflet position

Possible room for device selection and coronary protection for inoperable patients

Cylinder PorticoCoreValve

Moving Beyond Risk

Age-Life Expectancy-Valve Durability

Concomitant cardiac disease

Mitral valve disease

Coronary artery disease

Valve and Aortic Root Anatomy

LVOT Calcification

Small root-low lying coronary ostia

Bicuspid Aortic Valve

5/24/2017

13

Bicuspid Aortic Valve

2-3% of population

More common in the young

20% elderly patients with AS

25

Bicuspid Aortic Valve

Asymmetric cusps

More calcified

Asymmetric calcification

More circular annulus

Larger

Sinuses of Valsalva

STJ

Ascending aorta

26

Philip et al Catheterization and Cardiovascular Interventions 2015

5/24/2017

14

Bicuspid Aortic Valve

Device under-expansion

Higher rate of

Paravalvular leak

Second device

Annular rupture

Conversion to surgery

Improved with newer devices

Simulations?

Fate of the ascending aorta?

27

Yoon et al JACC 2015

Summary – So what is beyond STS score?

Clinical outcomes

Durability

Concomitant diseases

Mitral, Coronary, Other

Valve and Aortic Root Factors LVOT Calcification Low Lying Ostia Bicuspid

28

Directly impacts hemodynamics and

valve durability

5/24/2017

15

Acknowledgement

WMC Structural Heart Group – esp. Jennifer Dollery

Doctoral Students: Amir Azimian, Hoda Hatoum, Atieh Yousefi

Funding: NIH, DHLRI-Trifit

29